Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
PB Analistenconferentie
Volgen
Crucell Presents Update on Products and Programs at New York Analyst Meeting New York, November 16, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) today presents an update on the Company's strategy, organization, product sales, research and development programs, and financial outlook in a meeting with analysts and investors held in New York. A live audio webcast of the meeting, featuring the presentation slides, can be accessed via the homepage of Crucell's website at www.crucell.com , and will be archived and available for replay following the event. Crucell will continue to capitalize on the rapidly growing vaccine market through increasing sales of marketed vaccines and developing and introducing new vaccines. The Company is leveraging its PER.C6® technology in the rapidly growing protein market. On November 8, Crucell and DSM Biologics announced the opening of the PERCIVIA PER.C6® Development Center in Cambridge, Massachusetts. PERCIVIA will continue to further develop the PER.C6® technology and provide turnkey solutions for the production of pharmaceutical proteins to licensees utilizing the PER.C6® human cell line. In addition to licensing its technology, Crucell intends to develop its own products in the area of blood proteins, produced on PER.C6® technology. Crucell is pursuing research and development of the blood-clotting Factor V Leiden/Cambridge and is investigating production of improved versions of currently marketed proteins on its PER.C6® production platform. "Crucell is focused on future growth both organically and through acquisitions. We are optimizing our sales of marketed products and continue to generate acceptance of our technologies throughout the industry. We invest significantly in research and development for long-term upside," said Crucell's Chief Executive Officer, Ronald H.P. Brus MD. "We reiterate that our financial position remains strong and we aim to achieve cash breakeven in 2007." Product programs update Influenza Crucell is optimizing Inflexal® V through the use of the adjuvant ISCOM-MATRIX-M. The primary target group for the ISCOM-MATRIX-M adjuvanted seasonal vaccine are the elderly. In relation to pandemic vaccine, Crucell has received an EU grant to develop a virosome-ISCOM-MATRIX-M adjuvanted H5N1 vaccine. PER.C6®-based seasonal influenza vaccines, developed in partnership with sanofi pasteur, have entered Phase I studies in both healthy adults and in the elderly, both started in the third quarter 2006. Crucell is involved in different programs to address the pandemic threat of avian influenza. An egg-based H9N2 vaccine, developed with the University of Leicester, entered Phase I/II clinical studies in May 2006. Results are expected in the second half of 2007. The PER.C6®-based FLUPAN H7N1 Phase I study, comparing the cell-based vaccine to egg-based alternatives, started in September 2006. Children's vaccines Crucell's Quinvaxem(TM) vaccine was approved by the Korean FDA in March 2006 and received World Health Organization (WHO) pre-qualification in September 2006. The inclusion of Hepatitis B into this vaccine potentially allows additional childhood vaccines to be added to the childhood vaccination schedule. These vaccines could include a hepatitis A vaccine, a malaria vaccine or a tuberculosis vaccine. The pediatric dose of the hepatitis A vaccine Epaxal® has been shown in a phase III study to be effective in combination with other children's vaccines, providing immediate and long lasting protection. Our malaria vaccine has received all necessary approval to enter Phase I clinical study which is expected to start in the fourth quarter of 2006 at Vanderbilt University in the US. The clinical trial will be a randomized, double-blind, placebo-controlled study that will test the vaccine in a dose-escalation study involving 96 healthy volunteers. Studies in large animal models demonstrated that Crucell's recombinant Ad35 vaccine provides better immune responses than the existing RTS,S candidate vaccine. A PER.C6®-based tuberculosis vaccine developed in partnership with Aeras entered Phase I studies in the US in October 2006. The study is expected to be completed in 2007. Preclinical studies demonstrated that Crucell's recombinant Ad35 tuberculosis vaccine provided effective protection after a single shot. Travelers' vaccines and other programs Crucell's Epaxal® hepatitis A vaccine has a potential use for protecting travelers against hepatitis A when traveling to hepatitis A endemic regions. Crucell is currently negotiating with the US Food and Drug Administration for licensing Epaxal® in the US. Flavimun®, a vaccine against yellow fever, is currently in Phase III studies and is expected to be licensed and launched in 2007. Crucell's Ebola vaccine developed in partnership with the Vaccine Research Center (VRC) of the NIH, entered Phase I studies in September 2006. Phase I study results are expected in the fourth quarter 2007. The Company's anti-rabies monoclonal antibody cocktail has received IND approval in October 2006. Phase I studies are planned in the US starting in the fourth quarter of 2006 and in the Philippines in the first quarter of 2007. Crucell's West Nile virus vaccine is currently in a Phase I, double-blind, placebo- controlled study for adverse effects and immunogenicity. Results are expected in the fourth quarter 2006. Factor V Leiden/Cambridge (L/C) The Company acquired all the intellectual property rights for its novel Factor V Leiden/Cambridge program. Factor V L/C will be developed for the prevention and treatment of bleeding in haemophiliacs and non-haemophiliacs at high risk. The Company estimates the market potential for Factor V L/C at over US$3 billion. Financial Outlook The Company narrowed its guidance for combined revenue and other operating income for 2006 to €140 - €150 million. Due to the late start of the flu season the Company expects very strong fourth quarter revenues as a result of sales of its Inflexal® V influenza vaccine. Sales of Crucell's Quinvaxem(TM) started in October 2006. The total decrease in cash over 2006 will exceed the company's prior estimate of €33 million to €38 million by up to €14 million, as a result of the cash acquisition of Berna Products Corp, Inc. and related costs. The Company aims to achieve cash break-even in 2007. About Crucell Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spa
Factor V Leiden/Cambridge (L/C) The Company estimates the market potential for Factor V L/C at over US$3 billion. Financial Outlook The Company narrowed its guidance for combined revenue and other operating income for 2006 to €140 - €150 million. Wow
Dit is echt super nieuws. Wie gaat er hierop nu verkopen? Vandaag riching 21 volgens mij
Zeer goed nieuws. Vandaag zeker boven 20 en misschien wel meer.
Hallo, Crucell is duidelijk op weg een grote vis te worden. Helaas staan er ook enkele (voor mij) minder positieve elementen in dit PB, zijnde: - Hogere cash burn. - Er staan ons nog overnames te wachten. - Geen woord over STAR. Voor het overige niets dan lof. Greetz, Gert.
Ook nieuw & verrassend: West Nile resultaten van fase 1 klinisch onderzoek, worden reeds bekend gemaakt in kwartaal 4 van dit jaar! Positief nieuws t.a.v. West Nile - vooral een Amerikaans probleem - kan de koers opnieuw verder omhoog stuwen. grtz, ZEKER
Gerturo schreef:
Hallo,
Crucell is duidelijk op weg een grote vis te worden. Helaas staan er ook enkele (voor mij) minder positieve elementen in dit PB, zijnde:
- Hogere cash burn.
- Er staan ons nog overnames te wachten.
- Geen woord over STAR.
Voor het overige niets dan lof.
Greetz,
Gert.
Cash burn was nieuws van gisteren. Overname was al bijvoorbeeld door Wijma ingecalculeerd (Factor V). Hoeft niet negatief te zijn toch. STAR kan nog komen. Maar als er nog geen contract i, maar wel vorderingen of bijgestelde verwachtingen dan zou ik het ook niet in een PB zetten.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
911,51
-0,38%
EUR/USD
1,0856
-0,02%
FTSE 100
8.416,45
-0,09%
Germany40^
18.722,50
-0,25%
Gold spot
2.422,31
-0,16%
NY-Nasdaq Composite
16.794,87
+0,65%
Stijgers
Dalers